Affordable Access

deepdyve-link
Publisher Website

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

Authors
  • Bergh, Jonas
  • Jönsson, Per-Ebbe
  • Lidbrink, Elisabet Kerstin
  • Trudeau, Maureen
  • Eiermann, Wolfgang
  • Brattström, Daniel
  • Lindemann, Justin P O
  • Wiklund, Fredrik
  • Henriksson, Roger
Type
Published Article
Journal
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology
Publication Date
Jun 01, 2012
Volume
30
Issue
16
Pages
1919–1925
Identifiers
DOI: 10.1200/JCO.2011.38.1095
PMID: 22370325
Source
Medline
License
Unknown

Abstract

Fulvestrant (250 mg + LD regimen) in combination with anastrozole offered no clinical efficacy advantage over anastrozole monotherapy in this population of individuals with a relatively high proportion of previous adjuvant antiestrogen exposure.

Report this publication

Statistics

Seen <100 times